Is Novocure Stock Overvalued?
Medical device company Novocure's (NASDAQ: NVCR) shareholders have been cheering the company's recent success in its phase 3 clinical trial as the stock responded on the good news from an independent data monitoring company's positive findings. On a Fool Live episode recorded on April 14, Fool contributors Brian Feroldi and Brian Withers discuss the company's recent news and whether the stock is now overvalued.
Source Fool.com


